|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
US10941402B2
(en)
|
2016-09-01 |
2021-03-09 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded RNA-editing oligonucleotides
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
WO2021113270A1
(en)
|
2019-12-02 |
2021-06-10 |
Shape Therapeutics Inc. |
Therapeutic editing
|
|
MX2022006991A
(es)
*
|
2019-12-09 |
2022-08-25 |
Astellas Pharma Inc |
Arn guía antisentido con región funcional añadida para editar arn blanco.
|
|
WO2022103852A1
(en)
*
|
2020-11-11 |
2022-05-19 |
Shape Therapeutics Inc. |
Rna-editing compositions and methods of use
|
|
AU2022337146A1
(en)
|
2021-09-03 |
2024-03-14 |
Tacit Therapeutics, Inc. |
Rna editing via recruitment of spliceosome components
|
|
US20250084408A1
(en)
*
|
2021-10-27 |
2025-03-13 |
Shape Therapeutics Inc. |
Engineered rnas
|
|
EP4441219A2
(en)
*
|
2021-12-01 |
2024-10-09 |
Shape Therapeutics Inc. |
Engineered guide rnas and polynucleotides for rna editing targeting lrrk2
|
|
US20250154504A1
(en)
|
2022-02-14 |
2025-05-15 |
Proqr Therapeutics Ii B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
JP2025507958A
(ja)
|
2022-03-04 |
2025-03-21 |
ロックアネイビオ， インコーポレイテッド |
操作された核内低分子ＲＮＡ（ｓｎＲＮＡ）を含む組成物および方法
|
|
WO2023183825A2
(en)
*
|
2022-03-21 |
2023-09-28 |
Ptc Therapeutics Gt, Inc. |
Gene therapy of ush2a-associated diseases
|
|
GB202208387D0
(en)
*
|
2022-06-08 |
2022-07-20 |
Ucl Business Ltd |
Modified U7 snRNA construct
|
|
WO2024013360A1
(en)
|
2022-07-15 |
2024-01-18 |
Proqr Therapeutics Ii B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
EP4555086A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Oligonucleotides for adar-mediated rna editing and use thereof
|
|
CN120112640A
(zh)
*
|
2022-08-24 |
2025-06-06 |
塑造治疗公司 |
用于提高rna有效载荷转录的工程化构建体
|
|
CN120129747A
(zh)
*
|
2022-10-11 |
2025-06-10 |
广州瑞风生物科技有限公司 |
snRNA核酸分子及其应用
|
|
WO2024081411A1
(en)
*
|
2022-10-13 |
2024-04-18 |
Shape Therapeutics Inc. |
Engineered constructs for enhanced stability or localization of rna payloads
|
|
AU2023364059A1
(en)
*
|
2022-10-18 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods comprising programmable snrnas for rna editing
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
AR131145A1
(es)
|
2022-11-24 |
2025-02-19 |
Proqr Therapeutics Ii Bv |
Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
CA3276262A1
(en)
|
2022-12-09 |
2024-06-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2024137991A2
(en)
*
|
2022-12-23 |
2024-06-27 |
Shape Therapeutics Inc. |
Engineered guide rnas and polynucleotides
|
|
JP2026504808A
(ja)
*
|
2023-01-18 |
2026-02-10 |
アプター バイオ，インク． |
神経変性疾患の処置のためのポリヌクレオチド組成物および方法
|
|
EP4652278A1
(en)
*
|
2023-01-18 |
2025-11-26 |
Aptah Bio, Inc. |
Polynucleotide compositions and methods for treatment of cancer
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
EP4669753A1
(en)
|
2023-02-20 |
2025-12-31 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
WO2024206175A1
(en)
|
2023-03-24 |
2024-10-03 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
AU2024246572A1
(en)
|
2023-03-27 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
WO2024226860A2
(en)
*
|
2023-04-26 |
2024-10-31 |
Shape Therapeutics Inc. |
Small nuclear rna processing hairpins for small rna payloads
|
|
EP4713450A1
(en)
*
|
2023-05-15 |
2026-03-25 |
Shape Therapeutics Inc. |
Engineered constructs with cassette arrangements for increased transcription of rna payloads
|
|
WO2024256620A1
(en)
|
2023-06-16 |
2024-12-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|
|
WO2025007937A1
(zh)
*
|
2023-07-04 |
2025-01-09 |
广州瑞风生物科技有限公司 |
靶向USH2A pre-mRNA假外显子PE40的snRNA及其应用
|
|
WO2025051946A1
(en)
|
2023-09-07 |
2025-03-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2025080844A1
(en)
*
|
2023-10-11 |
2025-04-17 |
Emugen Therapeutics Llc |
Methods and compositions for altering mecp2 expression
|
|
WO2025104239A1
(en)
|
2023-11-16 |
2025-05-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
WO2025126158A2
(en)
*
|
2023-12-15 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods comprising small nuclear rna (snrna) targeting sod1
|
|
WO2025132708A1
(en)
|
2023-12-20 |
2025-06-26 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
WO2025190385A1
(zh)
*
|
2024-03-14 |
2025-09-18 |
上海拓界生物医药科技有限公司 |
靶向LRRK2的RNAi剂及其医药用途
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025211949A1
(ko)
*
|
2024-04-05 |
2025-10-09 |
재단법인대구경북과학기술원 |
ＳｅｒｐｉｎＡ１ｅ 단백질을 유효성분으로 포함하는 기억력, 인지기능 개선용 또는 뇌신경질환의 예방 또는 치료용 조성물
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|